RecruitingNCT06720870
An Italian Multicenter Retrospective Observational Study to Assess Effectiveness and Safety of Siltuximab for Patients with Castleman's Disease Treated in Italy in a Real-life Context
Sponsor
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Enrollment
65 participants
Start Date
Mar 1, 2023
Study Type
OBSERVATIONAL
Conditions
Summary
The study is a pilot, observational, retrospective, and (italian) multicenter study. The study will involve the collection of patient data from medical records for patients with Multicentric Castelman Disease Relapsed/Refractory who received treatment with at least one dose of siltuximab, as part of standard of care in a real-life context, from July 2016 till April 2022 in 31selected italian centres.
Eligibility
Min Age: 18 Years
Inclusion Criteria3
- Histologically confirmed diagnosis of R/R MCD HIV and HHV-8 negative patients who underwent siltuximab in a real-life context from July 2016 till April 2022.
- Age ≥ 18 yearsatenrollment
- Signature of written informed consent (where applicable)
Exclusion Criteria1
- \. R/R MCD patients who underwent siltuximab in a clinical trial context
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(12)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06720870